Insight and Advancement in Hereditary Retinal Degenerations 2001;99:271–300.
17. Hollander AI, Roepman R, et al., Leber congenital amaurosis: genes, proteins and disease mechanisms, Prog Retina Eye Res, 2008;27(4):391–419.
18. Leber T, Uber retinitis pigmentosa und angeborene amaurose, von Graefe’s Arch Ophthalmol, 1869;15:1–25.
19. Franceschetti A, Dieterle P, Diagnostic and prognostic importance of the electroretinogram in tapetoretinal degeneration with reduction of the visual field and hemeralopia, Confin Neurol, 1954;14:184–6.
20. Koenekoop RK, An overview of Leber congenital amaurosis: a model to understand human retinal development, Surv Ophthalmol, 2004;49:379–98.
21. Stone EM, Leber congenital amaurosis-a model for efficient genetic testing of heterogeneous disorders: LXIV Edward Jackson Memorial Lecture, Am J Ophthalmol, 2007;144:791–811.
22. Paunescu K, Wabbels B, Preising M, et al., Longitudinal and cross-sectional study of patients with early onset severe retinal dystrophy associated with RPE 65 mutations, Graefe’s Arch Clin Exp Ophthalmol, 2005;243:417–26.
23. Acland GM, Aguirre GD, Ray J, et al., Gene therapy restores vision in a canine model of childhood blindness, Nat Genet, 2001;28:92–5.
24. Narfström K, Katz ML, Bragadottir R, et al., Functional and structural recovery of the retina after gene therapy in the RPE65 null mutation dog, Invest Ophthalmol Vis Sci, 2003;44:1663–72
25. Narfström K, Katz ML, Ford M, et al., In vivo gene therapy in young and adult RPE65–/– dogs produces long-term visual improvement, J Hered, 2003;94:31–7.
26. Le Meur G, Stieger K, Smith AJ, et al., Restoration of vision in RPE65-deficient Briard dogs using an AAV serotype 4 vector that specifically targets the retinal pigmented epithelium, Gene Ther, 2007;14:292–303.
27. Aguirre GK, Komáromy AM, Cideciyan AV, et al., Canine and human visual cortex intact and responsive despite early retinal blindness from RPE65 mutation, PLoS Med, 2007;4:e230.
28. Bainbridge J, Smith AJ, Barker S, et al., Effect of gene therapy on visual function in Leber’s congenital amaurosis, N Engl J Med, 2008;358:2231–9.
29. Maguire AM, Simonelli F, Pierce AA, et al., Safety and efficacy of gene transfer for Leber’s congentital amaurosis, N Engl J Med, 2008;358;2240–8.
30. Forsius H, Krause U, Helve J, et al., Visual acuity in 183 cases of X-chromosomal retinoschisis, Can J Ophthalmol, 1973;8:385–93.
31. De La Chappelle A, Alitalo T, Forsius H, X-linked juvenile retinoschisis, In: Wright AF, Jay B, eds., Molecular Genetics of Inherited Eye Disorders, Switzerland: Harwood Academic Publishers, 1994;339–57.
32. Sauer CG, Gehrig A, Warneke-Wittstock R, et al. Positional cloning of the gene associated with X-linked juvenile retinoschisis, Nat Genet, 1997;17:164–70.
33. Grayson C, Reid SN, Ellis JA, et al., Retinoschisin, the X-linked retinoschisis protein, is a secreted photoreceptor protein, and is expressed and released by Weri-Rb1 cells, Hum Mol Genet, 2000;9:1873–9.
34. George ND, Yates JR, Bradshaw K, Moore AT, Infantile presentation of X linked retinoschisis, Br J Ophthalmol, 1995;79:653–7.
35. Pimenides D, George ND, Yates JR, et al., X-linked retinoschisis: clinical phenotype and RS1 genotype in 86 UK patients, J Med Genet, 2005;42:e35.
36. George ND, Yates JR, Moore AT, Clinical features in affected males with X-linked retinoschisis, Arch Ophthalmol, 1996;114:274–80.
37. Deutmann AF, The Hereditary Dystrophies of the Posterior Pole of the Eye, Assen: Van Gorcum, 1971.
38. Kellner U, Brummer S, Foerster MH, Wessing A, X-linked congenital retinoschisis, Graefe’s Arch Ophthalmol, 1990;228:432–7.
39. Regillo CD, Tasman WS, Brown GC, Surgical management of complications associated with X-linked retinoschisis, Arch Ophthalmol, 1993;111:1080–6.
40. Apushkin MA, Fishman GA, Use of dorzolamide for patients with X-linked retinoschisis, Retina, 2006;26:741–5.
41. Zeng Y, Takada Y, Kjellstrom S, et al., RS-1 gene delivery to an adult Rs1h knockout mouse model restores ERG b-wave with reversal of the electronegative waveform of X-linked retinoschisis, Invest Ophthalmol Vis Sci, 2004;45(9):3279–85.
42. Min SH, Molday LL, Seeliger MW, et al., Prolonged recovery of retinal structure/function after gene therapy in an Rs1h-deficient mouse model of X-linked juvenile retinoschisis, Mol Ther, 2005;12:644–51.
43. Blacharski PA, Newsome DA, eds., Fundus flavimaculatus. Retinal Dystrophies and Degenerations, New York: Raven Press, 1988;135–59.
44. Bonin P, Passot M, De Laey JJ, eds., Triolaire-Colton M-Th, Le signe du silence choroidien dans les degenerscences tapetoretiniennes posterieures. International Symposium on Fluorescein Angiography, Doc Ophthalmol Proc Ser, 1976;9:461–3.
45. Eage Jr RC, Lucier AC, Bernardino Jr VB, Yanoff M, Retinal pigment epithelial abnormalities in fundus flavimaculatus. A light and electron microscopic study, Ophthalmol, 1980;87:1189–200.
46. Valverde D, Riviero-Alvarez R, Aguirre-Lamban J, et al., Spectrum of the ABCA4 gene mutations implicated in severe retinopathies in Spanish patients, Invest Ophthalmol Vis Sci, 2007;48:985–90.
47. Beit-Ya’acov A, Mizrabi-Meissonnier L, Obolensky A, et al., Homozygosity for a novel ABCA4 founder splicing mutation is associated with progressive and severe Stargardt-like disease, Invest Ophthalmol Vis Sci, 2007;48:4308–14.
48. Sandberg MA, Jacobson SG, Berson EL, Foveal cone electroretinograms in retinitis pigmentosa and juvenile macular degeneration, Am J Ophthalmol, 1979;88:702–7.
49. Birnbach CD, Jarvelainen M, Possin DE, Milam AH, Histopathology and immunocytochemistry of the neurosensory retina in fundus flavimaculatus, Ophthalmol, 1994;101:1211–9.
50. Delori FC, Staurenghi G, Arend O, Dorey CK, In vivo measurement of lipofuscin in Stargardt’s disease—fundus flavimaculatus, Invest Ophthalmol Vis Sci, 1995;36:2327–31.
US OPHTHALMIC REVIEW
93
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112 |
Page 113 |
Page 114 |
Page 115 |
Page 116